Trials / Completed
CompletedNCT06877390
Effect of Enhanced External Counterpulsation
Effect of Enhanced External Counterpulsation on the Rehabilitation of Patients With Acute Myocardial Infarction After Drug-Coated Balloon-Based Percutaneous Coronary Intervention
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the efficacy and safety of enhanced extracorporeal counterpulsation for cardiac rehabilitation in patients after DCB for acute myocardial infarction.
Conditions
- Enhanced External Counterpulsation (EECP)
- Acute Myocardial Infarction (AMI)
- Drug-coated Balloon
- Cardiac Rehabilitation
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | conventional drug and exercise rehabilitation | patients in the control group received antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel, once a day), β-blocker (25-100 mg of metoprolol, twice a day, with the dose adjusted based on the patient's heart rate) and statins (10-20 mg of rosuvastatin, every night). In addition, the patients received exercise rehabilitation (e.g. aerobic, resistance and flexibility training) for 30-60 min, 3-5 times/week. |
| DEVICE | EECP-based rehabilitation regimen | Patients in the rehabilitation group received the same medication and exercise rehabilitation as the control group during the trial period after undergoing DCB-based PCI DCBs; in addition, they were provided with EECP treatment after 7 days of medication. The treatment adopted a P-ECP/TI EECP device with a pressure setting of 0.020-0.035 MPa. Based on patients' actual tolerance, the treatment pressure and inflation and exhaust times were adjusted to a diastolic/systolic blood pressure ratio of \>1.2 and a diastolic/systolic pressure area of 1.5-2.0. The treatment was applied daily for 1 hour, 6 days a week, for a total of 36 hours. |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
- First posted
- 2025-03-14
- Last updated
- 2025-03-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06877390. Inclusion in this directory is not an endorsement.